HighTower Advisors
BMRN icon

HighTower Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

HighTower Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5
Closed -$4K – 3426
2021
Q4 		$4K Buy
+5
New +$413 ﹤0.01% 3203

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HighTower Advisors's BMRN Position: Q2 2026 in Review

HighTower Advisors reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.4% in Q2 2026, selling an estimated $218K and leaving 43,302 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1635.

HighTower Advisors first reported a position in BMRN in Q4 2013 and has held it in 40 quarters since. The position peaked at $3.24M in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • HighTower Advisors held 43,302 shares of BioMarin Pharmaceuticals worth $2.48M as of Q2 2026.
  • HighTower Advisors sold 3,974 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $218K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #1635 holding.
  • HighTower Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2013 and has held it in 40 quarters since.
  • HighTower Advisors's BioMarin Pharmaceuticals position peaked at $3.24M in Q1 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.